SCN5A

SCN5A is a gene that encodes the alpha subunit of the cardiac sodium channel, which is crucial for the initiation and propagation of action potentials in cardiac muscle cells. This gene is located on the short arm of chromosome 3 (3p21) and plays a significant role in the electrical activity of the heart.

Function

The SCN5A gene encodes the alpha subunit of the voltage-gated sodium channel Nav1.5, which is predominantly expressed in cardiac tissue. This channel is responsible for the rapid influx of sodium ions during the initial phase of the cardiac action potential, leading to the depolarization of cardiac myocytes. Proper functioning of Nav1.5 is essential for maintaining normal cardiac rhythm and conduction.

Clinical Significance

Mutations in the SCN5A gene have been associated with a variety of cardiac arrhythmias and conditions, including:

• Long QT syndrome (LQT3): A condition characterized by prolonged cardiac repolarization, which can lead to syncope, seizures, or sudden cardiac death.
• Brugada syndrome: A disorder that causes abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death.
• Sick sinus syndrome: A group of heart rhythm disorders due to malfunction of the sinus node.
• Progressive cardiac conduction defect: Also known as Lenègre disease, this condition involves the progressive slowing of cardiac conduction.
• Dilated cardiomyopathy: A disease of the heart muscle that can lead to heart failure.

Pathophysiology

Mutations in SCN5A can lead to either gain-of-function or loss-of-function effects on the Nav1.5 channel. Gain-of-function mutations often result in prolonged sodium current, contributing to conditions like Long QT syndrome. Conversely, loss-of-function mutations can reduce sodium current, leading to Brugada syndrome or conduction defects.

Genetic Testing and Diagnosis

Genetic testing for SCN5A mutations is available and can be used to confirm a diagnosis in individuals with a family history of arrhythmias or sudden cardiac death. Identifying specific mutations can help guide treatment and management strategies.

Treatment

Management of conditions associated with SCN5A mutations may include lifestyle modifications, pharmacological interventions such as beta-blockers or antiarrhythmic drugs, and in some cases, the implantation of a pacemaker or defibrillator.

Research Directions

Ongoing research is focused on better understanding the molecular mechanisms by which SCN5A mutations lead to arrhythmias, as well as developing targeted therapies to correct or mitigate these effects.

Also see

• Voltage-gated sodium channel
• Cardiac action potential
• Arrhythmia
• Sudden cardiac death

Cardiovascular disease A-Z

Most common cardiac diseases

• Cardiac arrhythmia‎
• Cardiogenetic disorders‎
• Cardiomegaly‎
• Cardiomyopathy‎
• Cardiopulmonary resuscitation‎
• Chronic rheumatic heart diseases‎
• Congenital heart defects‎
• Heart neoplasia‎
• Ischemic heart diseases‎
• Pericardial disorders
• Syndromes affecting the heart‎
• Valvular heart disease‎

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

• Accelerated idioventricular rhythm
• Acute decompensated heart failure
• Arteriosclerotic heart disease
• Athletic heart syndrome
• Atrial flutter
• Atrioventricular fistula
• Cardiovascular disease in Australia
• Autoimmune heart disease

B

• Brown atrophy of the heart

C

• Ebb Cade
• Cardiac allograft vasculopathy
• Cardiac amyloidosis
• Cardiac asthma
• Cardiac tamponade
• Cardiogenic shock
• Cardiogeriatrics
• Cardiorenal syndrome
• Cardiotoxicity
• Carditis
• Coronary artery aneurysm
• Coronary artery anomaly
• Coronary artery disease
• Spontaneous coronary artery dissection
• Coronary artery ectasia
• Coronary occlusion
• Coronary steal
• Coronary thrombosis
• Coronary vasospasm
• Cœur en sabot
• Coxsackievirus-induced cardiomyopathy

D

• Duke Treadmill Score
• Duroziez's disease

E

• Eisenmenger's syndrome
• Embryocardia
• Endocardial fibroelastosis
• Eosinophilic myocarditis

H

• Heart attack
• Heart failure
• Heart failure with preserved ejection fraction
• Heart to Heart (1949 film)
• High-output heart failure
• Hyperdynamic precordium

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I

• Idiopathic giant-cell myocarditis
• Interventricular dyssynchrony
• Intraventricular dyssynchrony
• Isolated atrial amyloidosis

K

• Keshan disease

L

• Loeffler endocarditis

M

• Mydicar
• Myocardial bridge
• Myocardial disarray
• Myocardial rupture
• Myocardial scarring
• Myocardial stunning
• Myocarditis

N

• Nonbacterial thrombotic endocarditis

O

• OLR1
• Ostial disease

P

• Papillary fibroelastoma
• Pathophysiology of heart failure
• Postpericardiotomy syndrome
• Pulmonary vein stenosis

R

• Right axis deviation
• Roemheld syndrome

S

• Saturated fat and cardiovascular disease
• SCAR-Fc
• Shone's syndrome
• Strain pattern
• Subacute bacterial endocarditis
• Sudden cardiac death of athletes

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T

• Traumatic cardiac arrest

V

• Ventricular aneurysm
• Vibroacoustic disease
• Viral cardiomyopathy

W

• Waon therapy